Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $4.28 in the prior trading day, Oncology Institute Inc (NASDAQ: TOI) closed at $4.24%, Down $-0.93%. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 1.5 million shares were traded. TOI stock price reached its highest trading level at $4.375 during the session, while it also had its lowest trading level at $4.155.
Ratios:
Our goal is to gain a better understanding of TOI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.59 and its Current Ratio is at 1.79. In the meantime, Its Debt-to-Equity ratio is 20.18 whereas as Long-Term Debt/Eq ratio is at 18.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Noble Capital Markets on July 23, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
On July 16, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.
On May 15, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on May 15, 2025, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 05 ’25 when M33 Growth I L.P. sold 673,676 shares for $3.05 per share. The transaction valued at 2,054,712 led to the insider holds 13,950,557 shares of the business.
M33 Growth I L.P. sold 76,324 shares of TOI for $232,788 on Jun 05 ’25. The Director now owns 1,272,724 shares after completing the transaction at $3.05 per share. On Jun 03 ’25, another insider, Hively Brad, who serves as the Director of the company, sold 1,976,137 shares for $2.87 each. As a result, the insider received 5,672,106 and left with 603,501 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOI now has a Market Capitalization of 389714048 and an Enterprise Value of 441010624. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.97 while its Price-to-Book (P/B) ratio in mrq is 74.39. Its current Enterprise Value per Revenue stands at 1.094 whereas that against EBITDA is -9.698.
Stock Price History:
The Beta on a monthly basis for TOI is 0.13, which has changed by 6.7090907 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, TOI has reached a high of $4.50, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 38.68%, while the 200-Day Moving Average is calculated to be 172.20%.
Shares Statistics:
The stock has traded on average 2.15M shares per day over the past 3-months and 1891750 shares per day over the last 10 days, according to various share statistics. A total of 88.93M shares are outstanding, with a floating share count of 45.43M. Insiders hold about 50.57% of the company’s shares, while institutions hold 15.30% stake in the company. Shares short for TOI as of 1752537600 were 7145146 with a Short Ratio of 3.32, compared to 1749772800 on 2405246. Therefore, it implies a Short% of Shares Outstanding of 7145146 and a Short% of Float of 9.520000000000001.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
3 analysts predict $113.17M in revenue for the current quarter. It ranges from a high estimate of $116.6M to a low estimate of $110.35M. As of the current estimate, Oncology Institute Inc’s year-ago sales were $98.58MFor the next quarter, 3 analysts are estimating revenue of $121.25M. There is a high estimate of $122.6M for the next quarter, whereas the lowest estimate is $119.49M.
Based on 3 analysts’ estimates, the company’s revenue will be $556.23M in the next fiscal year. The high estimate is $582.35M and the low estimate is $536.33M.
